Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.62 |
| ▸ | HTR3A | P46098 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.59 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20024437 | 0.84 | SLC6A2 (0.78) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL16902875 | 0.84 | SLC6A2 (0.78) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL22168428 | 0.79 | SLC6A2 (0.71) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL14312038 | 0.79 | SLC6A2 (0.77) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL2299904 | 0.76 | KDM4E (0.42) | SLC6A2SLC6A4KCNH2SLC6A3TDP1 | |
| SCHEMBL2302428 | 0.75 | TAAR1 (0.52) | MAPK1HTTSMN1; SMN2 | |
| SCHEMBL2300975 | 0.75 | CHRNB4 (0.52) | MAPK1SMN1; SMN2 | |
| SCHEMBL2298298 | 0.75 | ALDH1A1 (0.42) | SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL23482986 | 0.74 | SLC6A2 (0.64) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 | |
| SCHEMBL2227832 | 0.74 | SLC6A2 (1.00) | SLC6A2SLC6A4HTR3AKCNH2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | SLC6A2 475/4885SLC6A4 502/4885HTR3A 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.